STAR-LLD

A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)

Arms / Cohorts

Experimental:Arm 1: Lenalidomide 400 mcg/h

Accepting patients

Experimental:Arm 2: Lenalidomide 300 mcg/h

Accepting patients

Experimental:Arm 3: Lenalidomide 500 mcg/h

Accepting patients

Experimental:Arm 4: Lenalidomide 600 mcg/h

Accepting patients

Active Comparator:Arm 5: Lenalidomide (Oral Capsule Control)

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.